Global, regional, and national trends in mesothelioma burden from 1990 to 2019 and the predictions for the next two decades

被引:3
作者
Zhu, Wenmin [1 ]
Liu, Jialin [1 ]
Li, Yiling [1 ]
Shi, Ziwei [1 ]
Wei, Sheng [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, 13 Hangkong Rd, Wuhan 430030, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
mesothelioma; Incidence; Mortality; Disability-adjusted life years; Projection; PERIOD-COHORT ANALYSIS; CANCER; ASBESTOS;
D O I
10.1016/j.ssmph.2023.101441
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives: We aimed to analyze the secular trends in mesothelioma burden, the effect of age, period, and birth cohort, and project the global burden over time.Material and methods: Based on the mesothelioma incidence, mortality, and Disability-Adjusted Life Years (DALYs) data from 1990 to 2019 in Global Burden of Diseases (GBD) database, the annual percentage change (APC) and average annual percent change (AAPC), calculated from joinpoint regression model, was used to describe the burden trends. An age-period-cohort model was utilized to disentangle age, period, and birth cohort effects on mesothelioma incidence and mortality trends. The mesothelioma burden was projected by the Bayesian age-period-cohort (BAPC) model.Results: Globally, there were the significant declines in age-standardized incidence rate (ASIR) (AAPC = -0.4, 95%CI: -0.6,-0.3, P < 0.001), age-standardized mortality rate (ASMR) (AAPC = -0.3, 95%CI: -0.4,-0.2, P < 0.001), and age-standardized DALY rate (ASDR) (AAPC = -0.5, 95%CI: -0.6,-0.4, P < 0.001) of mesothelioma overall 30 years. For regions, Central Europe presented the most distinct increases and the most substantial decrease was observed in Andean Latin America on all ASRs (age-standardized rates) from 1990 to 2019. At national level, the largest annualized growth for full-range trends of incidence, mortality, and DALYs was in Georgia. Conversely, the fastest descent of all ASRs was observed in Peru. The ASIR, ASMR, and ASDR in 2039 predicted 0.33, 0.27, and 6.90 per 100,000, respectively.Conclusions: The global burden of mesothelioma declined over the past 30 years, with variability across regions and countries/territories, and this trend will continue in the future.
引用
收藏
页数:8
相关论文
共 37 条
  • [1] Abbafati C, 2020, LANCET, V396, P1204
  • [2] Abbafati C, 2020, LANCET, V396, P1135, DOI 10.1016/S0140-6736(20)31404-5
  • [4] Malignant Mesothelioma Diagnosis
    Arif, Qudsia
    Husain, Aliya N.
    [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (08) : 978 - 980
  • [5] The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
    Banerji, Shantanu
    Meyers, Daniel E.
    Harlos, Craig
    Dawe, David E.
    [J]. CURRENT ONCOLOGY, 2021, 28 (06) : 4542 - 4551
  • [7] Towards sustainable healthcare system performance in the 21st century in high-income countries: a protocol for a systematic review of the grey literature
    Braithwaite, Jeffrey
    Zurynski, Yvonne
    Ludlow, Kristiana
    Holt, Joanna
    Augustsson, Hanna
    Campbell, Margie
    [J]. BMJ OPEN, 2019, 9 (01):
  • [8] Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
    Carbone, Michele
    Adusumilli, Prasad S.
    Alexander, H. Richard, Jr.
    Baas, Paul
    Bardelli, Fabrizio
    Bononi, Angela
    Bueno, Raphael
    Felley-Bosco, Emanuela
    Galateau-Salle, Francoise
    Jablons, David
    Mansfield, Aaron S.
    Minaai, Michael
    de Perrot, Marc
    Pesavento, Patricia
    Rusch, Valerie
    Severson, David T.
    Taioli, Emanuela
    Tsao, Anne
    Woodard, Gavitt
    Yang, Haining
    Zauderer, Marjorie G.
    Pass, Harvey, I
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2019, 69 (05) : 402 - 429
  • [9] Approved and emerging treatments of malignant pleural mesothelioma in elderly patients
    Ceresoli, Giovanni Luca
    Rossi, Antonio
    [J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (12) : 1179 - 1188
  • [10] High Time for Complete Ban on Asbestos Use in Developing Countries
    Chen, Tianhui
    Sun, Xiao-Ming
    Wu, Licun
    [J]. JAMA ONCOLOGY, 2019, 5 (06) : 779 - 780